A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
NCT ID: NCT06075615
Last Updated: 2025-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2024-09-30
2026-09-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is seeking participants who:
* have lung cancer that has reached at least the brain.
* have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work.
* have not received any treatment before.
All participants in this study will receive dacomitnib 1 time a day. Dacomitinib is a tablet that is taken by mouth at home. They can continue to take dacomitnib until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study of Dacomitinib in Progressive Brain Metastases
NCT02047747
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00470054
Dasatinib in Advanced Squamous Cell Lung Cancer
NCT01491633
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
NCT00094094
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
NCT00818441
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dacomitnib
dacomitnib
patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dacomitnib
patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* confirmed diagnosis of EGFR mutation-positive NSCLC
* at least one measurable intracranial metastasis
* ECOG-PS of 0, 1 or 2
* dacomitinib as first-line treatment for advanced NSCLC
* Evidence of a personally signed and dated informed consent document (ICD)
Exclusion Criteria
* currently on active investigational drug(s) treatment in other clinical studies (Phase 1-4) within 2 weeks before the current study begins and/or during study participation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT06075615
Identifier Type: REGISTRY
Identifier Source: secondary_id
A7471072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.